Brief: Knight Therapeutics Submits Crexont® (Carbidopa And Levodopa) Extended-Release Capsules In Mexico
05/08/2025 13:28
Aug 5 (Reuters) - Amneal Pharmaceuticals Inc AMRX.O: KNIGHT THERAPEUTICS ANNOUNCES REGULATORY SUBMISSION OF CREXONT® (CARBIDOPA AND LEVODOPA) EXTENDED-RELEASE CAPSULES IN MEXICO Source text: ID:nGNXc1N94q Further company coverage: AMRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Knight Therapeutics
See all newsBrief: Knight Therapeutics Announces Regulatory Approval Of Niktimvo In Brazil
Brief: Knight Therapeutics - Launches Tavalisse In Brazil For Chronic Immune Thrombocytopenia
Brief: Knight Therapeutics Enters Into Exclusive Distribution Agreement With Kyowa Kirin International For Poteligeo® (Mogamulizumab)
Brief: Knight Therapeutics Announces Regulatory Approval Of Tavalisse® In Colombia
Brief: Knight Therapeutics Announces Supplemental Regulatory Submission For Minjuvi In Brazil